The DOI matches its Crossref record; 47 of the 48 references it cites were found in a registry or an index; 34 of the 71 sources its claims cite were checked for support.
Efficacy and safety of once-weekly tirzepatide for weight management compared to placebo: An updated systematic review and meta-analysis including the latest SURMOUNT-2 trial
Open accessAbstract
AIM: Tirzepatide, a newly developed dual glucose-dependent insulinotropic peptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, has received approval for treating type 2 diabetes (T2D) and is currently being studied for its potential in long-term weight control. We aim to explore the safety and efficacy of once-weekly subcutaneous tirzepatide for weight loss in T2D or obese patients. METHODS: A comprehensive search was performed on various databases including PubMed, Embase, Cochrane Library, Web of Science, and ClinicalTrials.gov from inception up to April 29, 2024, to identify randomized controlled trials (RCTs) that assessed the efficacy of once-weekly tirzepatide compared to a placebo in adults with or without T2D. The mean difference (MD) and risk ratio (RR) were calculated for continuous and dichotomous outcomes, respectively. The risk of bias was evaluated using the RoB-2 tool (Cochrane), while the statistical analysis was conducted utilizing RevMan 5.4.1 software. RESULTS: Seven RCTs comprising 4795 individuals ranging from 12 to 72 weeks were identified. Compared to the placebo group, tirzepatide at doses of 5, 10, and 15 mg demonstrated significant dose-dependent weight loss. The mean difference (MD) in the percentage change in body weight (BW) was -8.07% (95% CI -11.01, -5.13; p < 0.00001), -10.79% (95% CI -13.86, -7.71; p < 0.00001), and -11.83% (95% CI -14.52, -9.14; p < 0.00001), respectively. Additionally, the MD in the absolute change in BW was -7.5 kg (95% CI -10.9, -4.1; p < 0.0001), -11.0 kg (95% CI -16.9, -5.2; p = 0.0002), and -11.5 kg (95% CI -16.2, -6.7; p < 0.00001), for the 5, 10, and 15 mg doses, respectively. All three doses of tirzepatide also significantly reduced body mass index and waist circumference. Furthermore, it led to a greater percentage of patients experiencing weight loss exceeding 5, 10, 15, 20, and 25%. Moreover, tirzepatide showed great success in reducing blood pressure, blood sugar levels, and lipid profiles. In terms of safety, gastrointestinal side effects were the most frequently reported adverse events in all three doses of tirzepatide groups, which were generally mild-to-moderate and transient. CONCLUSION: Tirzepatide treatment could lead to remarkable and sustained weight loss that is well-tolerated and safe, representing a novel and valuable therapeutic strategy for long-term weight management.
Overview
CoChat Summary
TL;DR
This updated meta-analysis of 7 randomized controlled trials (4,795 participants) found that once-weekly tirzepatide produced dose-dependent weight loss versus placebo and improved several cardiometabolic markers. The main tradeoff was more gastrointestinal adverse events, while serious adverse events and hypoglycemia were not increased.
Key findings
- Across 7 RCTs (4,795 participants; 12–72 weeks), tirzepatide reduced percentage body weight versus placebo by −8.07% with 5 mg, −10.79% with 10 mg, and −11.83% with 15 mg, all p < 0.00001.
- Absolute body weight change versus placebo was −7.5 kg, −11.0 kg, and −11.5 kg for 5, 10, and 15 mg, respectively.
- More participants achieved clinically meaningful weight loss with tirzepatide: ≥5% loss was 75.8%, 81.6%, and 84.3% for 5, 10, and 15 mg, versus 26.4%/27.9% with placebo; ≥20% loss in SURMOUNT-1 and SURMOUNT-2 reached 30%, 40.7%, and 48.1% for 5, 10, and 15 mg, versus 3.1%/2.4% with placebo; ≥25% loss was 15.2%, 24.6%, and 29.3% versus 1.6%/1.1%.
- Tirzepatide also improved BMI, waist circumference, SBP, HbA1c, fasting plasma glucose, and fasting lipids; gastrointestinal adverse events were the most common safety issue, with adverse events more frequent than placebo, but serious adverse events and hypoglycemia were not significantly different.
Methods
- Systematic review and meta-analysis conducted according to PRISMA 2020, with PROSPERO registration (CRD42023458081).
- Searched PubMed, Embase, Cochrane Library, Web of Science, and ClinicalTrials.gov up to April 29, 2024 for English-language RCTs in adults with or without T2D comparing once-weekly subcutaneous tirzepatide (5/10/15 mg) with placebo.
- Used mean differences for continuous outcomes and risk ratios for dichotomous outcomes; risk of bias was assessed with RoB-2, certainty with GRADE, and all pooled analyses used a random-effects model in RevMan 5.4.1.
Limitations
- The paper states it relied on published, study-level data rather than real-world patient data, and all included RCTs were supported by the pharmaceutical industry, which may overestimate benefit due to reporting bias.
- It states the effect of differing exercise and dietary regimens could not be quantified or assessed, and that most studies included selected diabetic populations rather than general non-diabetic populations.
- It states sample size and the number of included studies were limited, and that most research came from North/South America, Europe, and Japan with primarily Caucasian participants, limiting generalizability.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
23 Valid · 2 Not valid · 14 Not checked · 106 Own results and interpretations
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Due to the limited and poor long-term adherence to weight loss effects of lifestyle interventions”
§ Efficacy and safety of once-weekly tirzepatide for weight management compared to placebo: An updated systematic review and meta-analysis including the latest SURMOUNT-2 trial > Introduction
What the sources say
- Supportedcites [7] M. Lemstra, Y. Bird, C. Nwankwo et al. Weight loss intervention adherence and factors promoting adherence: a meta-analysis. Patient Preference Adherence 10, 1547–1559 (2016). https://doi.org/10.2147/ppa.S103649 source
The Interpretation says nonadherence to weight-loss interventions is usually high and explicitly includes lifestyle interventions combining diet and exercise. The Results (Subgroup analysis) report lower adherence for interventions lasting at least 12 months than for shorter interventions. (LLM, conf=0.88)
- Not checked — no full text of the sourcecites [8] Q. Zeng, N.S. Li, X.F. Pan et al. Clinical management and treatment of obesity in China. Lancet Diab. Endocrinol. 9(6), 393–405 (2021) source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“and the low public acceptance of bariatric surgery”
§ Efficacy and safety of once-weekly tirzepatide for weight management compared to placebo: An updated systematic review and meta-analysis including the latest SURMOUNT-2 trial > Introduction
What the sources say
- Could not verifycites [7] M. Lemstra, Y. Bird, C. Nwankwo et al. Weight loss intervention adherence and factors promoting adherence: a meta-analysis. Patient Preference Adherence 10, 1547–1559 (2016). https://doi.org/10.2147/ppa.S103649 sourceExperimental — accuracy not yet measured
The Introduction (page unavailable) discusses commonly reported weight-loss methods, and the Interpretation (page unavailable) discusses adherence to diet, exercise, and lifestyle interventions. Searches for bariatric surgery and public acceptance found no passage addressing public acceptance of the surgery. (LLM, conf=0.72)
- Not checked — no full text of the sourcecites [8] Q. Zeng, N.S. Li, X.F. Pan et al. Clinical management and treatment of obesity in China. Lancet Diab. Endocrinol. 9(6), 393–405 (2021) source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Seven studies [11, 12, 16–20] ultimately met all selection criteria and were included in the meta-analysis.”
§ Efficacy and safety of once-weekly tirzepatide for weight management compared to placebo: An updated systematic review and meta-analysis including the latest SURMOUNT-2 trial > Results > Search results
What the sources say
- Not checked — no full text of the sourcecites [11] J.P. Frias, M.A. Nauck, J. Van et al. Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial. Lancet (Lond., Engl.) 392(10160), 2180–2193 (2018). https://doi.org/10.1016/S0140-6736(18)32260-8 source
- Not checked — no full text of the sourcecites [12] A.M. Jastreboff, L.J. Aronne, N.N. Ahmad et al. Tirzepatide once weekly for the treatment of obesity. N. Engl. J. Med. 387(3), 205–216 (2022). https://doi.org/10.1056/NEJMoa2206038 source
- Supportedcites [16] J.P. Frias, M.A. Nauck, J. Van et al. Efficacy and tolerability of tirzepatide, a dual glucose-dependent insulinotropic peptide and glucagon-like peptide-1 receptor agonist in patients with type 2 diabetes: a 12-week, randomized, double-blind, placebo-controlled study to evaluate different dose-escalation regimens[J]. Diab. Obes. Metab. 22(6), 938–946 (2020). https://doi.org/10.1111/dom.13979 source
The citation identifies a study included in the citing authors’ meta-analysis; it does not ask this trial to verify the meta-analysis’s selection process or seven-study count. The Objectives (section 2.4) identify the source as a tirzepatide study comparing treatment groups with placebo in patients with type 2 diabetes, consistent with its use as an included study. (LLM, conf=0.87)
- Not checked — no full text of the sourcecites [17] T. Heise, A. Mari, J.H. DeVries et al. Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel-arm, phase 1 clinical trial. Lancet Diab. Endocrinol. 10(6), 418–429 (2022). https://doi.org/10.1016/S2213-8587(22)00085-7 source
- Not checked — no full text of the sourcecites [18] J. Rosenstock, C. Wysham, J.P. Frías et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet (Lond., Engl.) 398(10295), 143–155 (2021). https://doi.org/10.1016/S0140-6736(21)01324-6 source
- Supportedcites [19] D. Dahl, Y. Onishi, P. Norwood et al. Effect of subcutaneous tirzepatide vs placebo added to titrated insulin glargine on glycemic control in patients with type 2 diabetes: the SURPASS-5 randomized clinical trial. JAMA 327(6), 534–545 (2022). https://doi.org/10.1001/jama.2022.0078 source
The Methods section identifies this paper as a randomized, placebo-controlled tirzepatide study, so it supports the citation’s role in identifying one of the studies. The count of seven and the meta-analysis selection decision are statements by the citing authors, not findings attributed to this trial. (LLM, conf=0.88)
- Supportedcites [20] W.T. Garvey, J.P. Frias, A.M. Jastreboff et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet (Lond., Engl.) 402(10402), 613–626 (2023). https://doi.org/10.1016/S0140-6736(23)01200-X source
The Trial design and participants section (page not available) identifies SURMOUNT-2 as a randomised, placebo-controlled trial. In this multi-citation sentence, this paper serves as one of the studies cited for inclusion, not as the source of the count of seven or the meta-analysis’s selection criteria. (LLM, conf=0.86)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Every source the paper cites for this claim was checked and supports it.
In the paper
“Semaglutide 2.4 mg, a recently approved selective GLP-1RA for long-term weight management in obese adults, has shown greater effectiveness compared to these earlier AOMs [27].”
§ Efficacy and safety of once-weekly tirzepatide for weight management compared to placebo: An updated systematic review and meta-analysis including the latest SURMOUNT-2 trial > Discussion
What the sources say
- Supportedcites [27] J. Wilding, R. Batterham, S. Calanna et al. Once-weekly semaglutide in adults with overweight or obesity. : N. Engl. J. Med. 384, 989–1002 (2021) source
The Discussion reports 14.9% mean weight loss with semaglutide 2.4 mg, substantially greater than the 4.0–10.9% reported for approved anti-obesity medications. This supports the claim as a comparison of weight-loss effectiveness, although it is not a head-to-head trial comparison. (LLM, conf=0.92)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Consistent with this, the degree of weight loss achieved with tirzepatide 10 and 15 mg in individuals with obesity and T2D in SURMOUNT-2(12.8 and 14.7%) was lower than that observed in SURMOUNT-1 without T2D (19·5 and 20·9%, respectively) [12, 20].”
§ Efficacy and safety of once-weekly tirzepatide for weight management compared to placebo: An updated systematic review and meta-analysis including the latest SURMOUNT-2 trial > Discussion
What the sources say
- Not checked — no full text of the sourcecites [12] A.M. Jastreboff, L.J. Aronne, N.N. Ahmad et al. Tirzepatide once weekly for the treatment of obesity. N. Engl. J. Med. 387(3), 205–216 (2022). https://doi.org/10.1056/NEJMoa2206038 source
- Supportedcites [20] W.T. Garvey, J.P. Frias, A.M. Jastreboff et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet (Lond., Engl.) 402(10402), 613–626 (2023). https://doi.org/10.1016/S0140-6736(23)01200-X source
The Discussion explicitly compares the 10 mg and 15 mg doses: SURMOUNT-1 participants without type 2 diabetes lost 19.5% and 20.9% of body weight, versus 12.8% and 14.7% in SURMOUNT-2 participants with type 2 diabetes. This matches the attributed comparison and all four figures. (LLM, conf=0.95)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
88 more claims · 7 with their cited sources checked
Create a free account to see all 145 claims and every source verdict.
- Probably not a substantial claim. 16
- It may state two separate claims as one. 41
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“has been shown to produce ≈12% to 21% weight loss in patients with obesity.22”
From Effects of Tirzepatide on the Clinical Trajectory of Patients With Heart Failure, Preserved Ejection Fraction, and Obesity (2025) · cites this paper as [22]
Citations
Cites
The PRISMA 2020 statement: An updated guideline for reporting systematic reviews
Page, M. J., McKenzie, J. E., Bossuyt, P. M., Boutron, I., Hoffmann, T. C., Mulrow, C. D., Shamseer, L., Tetzlaff, J. M., Akl, E. A., Brennan, S. E., et al. (2021) · BMJ · doi:10.1136/bmj.n71 · Cited by 108,283
RoB 2: a revised tool for assessing risk of bias in randomised trials
Sterne, J. A. C., Savović, J., Page, M. J., Elbers, R. G., Blencowe, N. S., Boutron, I., Cates, C. J., Cheng, H.-Y., Corbett, M. S., Eldridge, S. M., et al. (2019) · BMJ · doi:10.1136/bmj.l4898 · Cited by 34,787 · cited 1×
“The methodological quality of each included RCT was assessed using the Cochrane Collaboration Risk of Bias 2 (RoB-2) tool [15].”
MethodSterne, J. A. C., Sutton, A. J., Ioannidis, J. P. A., Terrin, N., Jones, D. R., Lau, J., Carpenter, J., Rucker, G., Harbord, R. M., Schmid, C. H., et al. (2011) · BMJ · doi:10.1136/bmj.d4002 · Cited by 7,709 · cited 1×
“Consequently, the Egger test was not employed to formally assess funnel plot asymmetry, as it is not recommended for such small numbers of studies [25].”
MethodOnce-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205
Tirzepatide Once Weekly for the Treatment of Obesity
Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2206038 · Cited by 3,838 · cited 10×
“The majority of the research analyzed the effectiveness of tirzepatide in treating T2D, with BW alteration as a secondary outcome, except for SURMOUNT-1 [12] and SURMOUNT-2 [20], which primarily tested tirzepatide for the treatment of obesity.”
BackgroundMethodResultInfluentialObesity and cardiovascular disease: a scientific statement from the American Heart Association
Powell-Wiley, T. M., Poirier, P., Burke, L. E., Després, J.-P., Gordon-Larsen, P., Lavie, C. J., Lear, S. A., Ndumele, C. E., Neeland, I. J., Sanders, P., et al. (2021) · Circulation · doi:10.1161/cir.0000000000000973 · Cited by 3,691
Gerstein, H. C., Colhoun, H. M., Dagenais, G. R., Diaz, R., Lakshmanan, M., Pais, P., Probstfield, J., Riesmeyer, J. S., Riddle, M. C., Rydén, L., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31149-3 · Cited by 3,163 · cited 1×
“…trial (NCT04255433) is anticipated to yield conclusive answers regarding tirzepatide ’ s effect on major cardiovascular events when compared to dulaglutide, a long-acting GLP-1 RA that has demonstrated cardioprotective properties in people with T2D who are at high cardiovascular risk [40].”
BackgroundDi Angelantonio, E., Bhupathiraju, S. N., Wormser, D., Gao, P., Kaptoge, S., de Gonzalez, A. B., Cairns, B. J., Huxley, R., Jackson, C. L., Joshy, G., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30175-1 · Cited by 2,821 · cited 1×
“Excess adiposity is associated with a signi fi cantly increased risk of numerous complications, including type 2 diabetes(T2D), hypertension, cardiovascular diseases, non-alcoholic steatohepatitis, dyslipidemia, orthopedic issues, and reduced life expectancy [4, 5].”
BackgroundA Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C. W., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411892 · Cited by 2,724 · cited 1×
“The safety pro fi le observed was consistent with fi ndings from other incretin-based therapies, particularly similar to the safety pro fi le of GLP-1RA like liraglutide and semaglutide used for obesity treatment [27, 42].”
ResultTirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
Frías, J. P., Davies, M. J., Rosenstock, J., Pérez Manghi, F. C., Fernández Landó, L., Bergman, B. K., Liu, B., Cui, X., & Brown, K. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107519 · Cited by 2,096 · cited 1×
“The estimated treatment differences in weight loss between the 5 ‐ mg, 10 ‐ mg, and 15 ‐ mg tirzepatide groups and the semaglutide 1 mg group were − 1.9, − 3.6, and − 5.5 kg, respectively [30].”
BackgroundInfluential
Research works printed but not linked: 1
- H. Patel, K. Khunti, H.W. Rodbard et al. Tirzepatide-induced weight loss in type 2 diabetes is independent of nausea, vomiting, or diarrhoea. Diabetologia 65(abstr 568), 290–91 (2022).
Cited by
Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity
Packer, M., Zile, M. R., Kramer, C. M., Baum, S. J., Litwin, S. E., Menon, V., Ge, J., Weerakkody, G. J., Ou, Y., Bunck, M. C., et al. (2025) · New England Journal of Medicine · doi:10.1056/nejmoa2410027 · Cited by 1,009
Zile, M. R., Borlaug, B. A., Kramer, C. M., Baum, S. J., Litwin, S. E., Menon, V., Ou, Y., Weerakkody, G. J., Hurt, K. C., Kanu, C., et al. (2025) · Circulation · doi:10.1161/circulationaha.124.072679 · Cited by 74
Ndumele, C. E., Rodriguez, F., Dixon, D. L., Khan, S. S., Mukherjee, D., Bajaj, M., Bangalore, S., Bozkurt, B., Breathett, K., Clarke, S. L., et al. (2026) · JACC · doi:10.1016/j.jacc.2026.03.056 · Cited by 90
Ndumele, C. E., Rodríguez, F., Dixon, D. L., Khan, S. S., Mukherjee, D., Bajaj, M. S., Bangalore, S., Bozkurt, B., Breathett, K. K., Clarke, S. L., et al. (2026) · Circulation · doi:10.1161/cir.0000000000001453 · Cited by 146
Packer, M., Zile, M. R., Kramer, C. M., DiMaria, J. M., Baum, S. J., Litwin, S. E., Murakami, M., Zhou, C., Ou, Y., Koeneman, L., et al. (2025) · JACC · doi:10.1016/j.jacc.2025.06.058 · Cited by 34
Metadata
- Authors
- Qin, W., Yang, J., Ni, Y., Deng, C., Ruan, Q., Ruan, J., Zhou, P., & Duan, K.
- Affiliations
- Huazhong University of Science and Technology (CN)
- Wuhan Union Hospital (CN)
- Corresponding author
- Zhou, Peng
- Duan, Kai
- Venue
- Endocrine
- Published
- 2024-06-08
- Volume
- 86
- Issue
- 1
- Pages
- 70-84
- ISSN
- 0969-711X (ISSN-L)
- 1559-0100
- PMC
- PMC11445313
- OpenAlex
- W4399462567
- Cited by
- 55
- References
- 48
- Citations by year
- 2026: 21 · 2025: 28 · 2024: 5
- FWCI
- 5.34
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Endocrine (publishedVersion, cc-by)
- PubMed (publishedVersion)
- PubMed Central (submittedVersion, cc-by)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Surgery › Bariatric Surgery and Outcomes
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Keywords
- tirzepatide, weight loss, obesity, type 2 diabetes, GIP/GLP-1 receptor agonist, body weight, adverse events, drug safety
- MeSH terms
- Glucagon-Like Peptide-2 Receptor, Glucagon-Like Peptide-1 Receptor Agonists, Tirzepatide, Diabetes Mellitus, Type 2, Gastric Inhibitory Polypeptide
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-09-30, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-09-30 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Efficacy and safety of once-weekly tirzepatide for weight management compared to placebo: An updated systematic review and meta-analysis including the latest SURMOUNT-2 trial. https://app.cochat.ai/papers/10.1007/s12020-024-03896-z
- The paper
- Qin, W., Yang, J., Ni, Y., Deng, C., Ruan, Q., Ruan, J., Zhou, P., & Duan, K. (2024). Efficacy and safety of once-weekly tirzepatide for weight management compared to placebo: An updated systematic review and meta-analysis including the latest SURMOUNT-2 trial. Endocrine. https://doi.org/10.1007/s12020-024-03896-z
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.